Regeneron Pharmaceuticals Inc. ($REGN) Stock Forecast: Down 9.7% Today

What is Regeneron Pharmaceuticals Inc.?

Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) is a biotechnology company known for developing innovative treatments and therapies. The stock had a strong bearish movement today.

Why is Regeneron Pharmaceuticals Inc. going down?

REGN stock is down 9.7% on Oct 31, 2024 19:48

• Despite reporting better-than-expected third-quarter results with increased earnings and revenue, REGN experienced a bearish movement.
• The market may have reacted negatively due to investors possibly having higher expectations or concerns about future growth prospects.
• Even though the company's performance was strong, market sentiment and external factors could have influenced the stock's decline.
• It's essential for investors to consider both the company's financial results and market dynamics when analyzing stock movements.

REGN Price Chart

REGN Technical Analysis

REGN News

Why Is Regeneron Pharmaceuticals Stock Trading Lower Today? - Regeneron Pharmaceuticals ( NASDAQ:REGN )

On Thursday, Regeneron Pharmaceuticals Inc REGN reported third-quarter adjusted EPS of $12.46, up 8% year-over-year, beating the consensus of $11.69. The company reported sales of $3.72 billion, up 11%, beating the consensus of $3.67 billion. "Regeneron had a strong third quarter marked by 11% ...

https://www.benzinga.com/general/biotech/24/10/41660999/why-is-regeneron-pharmaceuticals-stock-trading-lower-today

REGN Q3 Earnings and Revenues Beat on Strong Eylea HD & Dupixent Sales

Regeneron reports better-than-expected third-quarter results, beating earnings and revenue estimates, driven by strong Eylea HD, Dupixent and Libtayo sales.

https://www.zacks.com/stock/news/2361953/regn-q3-earnings-and-revenues-beat-on-strong-eylea-hd-dupixent-sales

Regeneron to Report Q3 Earnings: What's in the Offing?

Investors' focus is likely to be on the performance of Dupixent and the uptake of Eylea HD when REGN reports third-quarter 2024 results.

https://www.zacks.com/stock/news/2358965/regeneron-to-report-q3-earnings-whats-in-the-offing

Top Stocks To Buy Now? 2 Biotech Stocks To Watch

The biotech sector represents companies developing innovative treatments and therapies using biological processes. These firms range from early-stage research companies to established pharmaceutical developers. Biotech stocks offer investment opportunities in companies working on groundbreaking ...

https://stockmarket.com/featured/top-stocks-to-buy-now-2-biotech-stocks-to-watch-2024-10-28

Trending Today

Unity Software ($U) Stock Forecast: Up 5.1% Today

Pepe ($PEPE) Crypto Forecast: Up 6.0% Today

Dogecoin ($DOGE) Crypto Forecast: Up 9.0% Today

Affirm Holdings Inc. ($AFRM) Stock Forecast: Up 5.0% Today

Vimeo, Inc. ($VMEO) Stock Forecast: Up 45.0% Today

Super Micro Computer Inc ($SMCI) Stock Forecast: Up 5.0% Today

Novavax Inc. ($NVAX) Stock Forecast: Up 5.5% Today

Cleveland-Cliffs Inc. ($CLF) Stock Forecast: Down 10.6% Today

dogwifhat ($WIF) Crypto Forecast: Up 6.0% Today

Shiba Inu ($SHIB) Crypto Forecast: Up 7.3% Today

Regeneron Pharmaceuticals Inc. Price History

31.09.2024 - REGN Stock was down 9.7%

• Despite reporting better-than-expected third-quarter results with increased earnings and revenue, REGN experienced a bearish movement.
• The market may have reacted negatively due to investors possibly having higher expectations or concerns about future growth prospects.
• Even though the company's performance was strong, market sentiment and external factors could have influenced the stock's decline.
• It's essential for investors to consider both the company's financial results and market dynamics when analyzing stock movements.

31.09.2024 - REGN Stock was down 6.9%

• The recent bearish movement in REGN may be linked to investor caution preceding the third-quarter earnings. Concerns may arise regarding the performance of key products like Dupixent and the adoption of Eylea HD.
• While REGN has displayed long-term market outperformance, short-term fluctuations can be influenced by quarterly outcomes and investor sentiment.
• Amid uncertainties in the biotech sector and broader market conditions, investors could be reassessing their positions in REGN.

24.08.2024 - REGN Stock was down 8.1%

• Smart money has shown bearish behavior with REGN options, indicating a bearish sentiment among traders.
• This change in sentiment from financial giants may have contributed to REGN's bearish movement.
• Analyst downgrades for companies like Baidu Inc. (NYSE: BIDU) could impact overall market sentiment, indirectly influencing REGN's stock performance.
• The strong bearish movement in REGN today appears to be influenced by negative analyst outlook and bearish options activity.

24.08.2024 - REGN Stock was down 6.8%

• Chief District Judge Thomas Kleeh's rejection of Regeneron Pharmaceuticals' attempt to halt the sale of Amgen Inc's Eylea biosimilar likely influenced the bearish movement in REGN stock.
• The options market exhibited a notable bearish trend toward Regeneron Pharmaceuticals, indicating a considerable number of traders expressing bearish views.
• The prevailing negative market sentiment, portrayed by analyst downgrades affecting companies like BP and Baidu, potentially intensified the downward pressure on REGN stock.
• Investors are keeping a close watch on the legal proceedings and options market sentiment to assess the future direction of Regeneron Pharmaceuticals' stock.

23.08.2024 - REGN Stock was down 5.1%

• Smart money is betting big on bearish options for REGN, with a notable increase in bearish trades.
• The high percentage of bearish traders indicates a prevailing sentiment of negativity towards REGN in the options market.
• This bearish movement could be attributed to concerns or uncertainties surrounding Regeneron Pharmaceuticals' future prospects or recent developments within the company.
• Investors might be reacting to specific news or events that have cast a shadow on REGN's short-term outlook, leading to the bearish market movement.

31.09.2024 - REGN Stock was down 10.8%

• REGN's Q3 earnings and revenues exceeded expectations, attributed to robust sales of Eylea HD and Dupixent.
• The market exhibited a bearish reaction post-results, possibly due to profit-taking following a period of solid performance.
• Concerns around REGN's growth sustainability and industry competition might have fueled investor caution, contributing to the bearish sentiment.
• Short-term dynamics appear to influence the market's sentiment towards REGN, possibly diminishing focus on the company's solid fundamentals and product range.

20.02.2024 - REGN Stock was up 0.4%

• REGN stock experienced a strong bullish movement today.
• The bullish trend in REGN could be attributed to positive news surrounding the biotech industry, such as recent developments in a phase III study and the overall recovery of the biotech sector.
• The selling of over $5.5 million in stock by Regeneron's EVP research may have initially raised concerns but did not deter investors from driving the stock price higher.
• The bearish stance taken by some investors on REGN through options trading might have created short-term volatility, but the overall positive sentiment in the biotech market overshadowed this, leading to the bullish movement in REGN today.

03.05.2024 - REGN Stock was up 2.1%

• The bullish movement in REGN stock today can be attributed to the following factors:
• The FDA's decision to delay the verdict on Dupixent in COPD until September may have created anticipation and optimism among investors, as it indicates the regulatory body's thorough review and potential positive outcome.
• The recommendation for EU approval of Dupixent to treat COPD patients by CHMP could have boosted investor confidence in the drug's efficacy and market potential.
• The announcement of Neurocrine's CEO stepping down might have indirectly impacted REGN's stock positively, as it could signal upcoming strategic changes within the pharmaceutical industry that investors perceive as favorable.
• Overall, these developments surrounding Dupixent and regulatory approvals suggest a promising future for Regeneron Pharmaceuticals, driving the bullish market movement observed today.

27.10.2023 - REGN Stock was up 2.0%

• REGN's bullish movement today can be attributed to the news that Sanofi and Regeneron are set to file for FDA approval of Dupixent for the treatment of chronic obstructive pulmonary disease (COPD). This potential expansion of Dupixent's use could significantly boost REGN's growth prospects.
• The positive results from a second large trial of Dupixent in COPD, which showed a 34% reduction in exacerbations of the disease, further supported the potential approval and wider use of the drug.
• The increase in REGN's stock could also be influenced by the growing interest from institutional investors, such as The Manufacturers Life Insurance Company, which acquired additional shares of the company during the 2nd quarter.
• Overall, REGN's bullish movement today can be attributed to the positive developments surrounding Dupixent and its potential expansion into treating COPD, as well as the growing confidence from institutional investors.

25.03.2024 - REGN Stock was down 3.4%

• Despite an increase in the price target for Regeneron stock, the market may have reacted negatively to the recent pullback, leading to the bearish movement.
• A change in the rating from "strong-buy" to "buy" could have influenced investor sentiment and contributed to the downward pressure on the stock.
• The focus on genetic medicine research advancements and promising early results in gene therapy programs at a recent conference may have not been enough to offset the overall market sentiment.
• An industry comparison analysis might have highlighted challenges or weaknesses in Regeneron Pharmaceuticals compared to its competitors, impacting the stock's performance negatively.

01.07.2024 - REGN Stock was up 3.6%

• REGN stock showed significant upward momentum recently.
• This positive trend is due to Regeneron exceeding expectations in its latest financial results, fueled by strong demand for its eczema and eye treatments.
• The company posted impressive Q2 2024 financial and operational figures, including a notable rise in net income and revenue, alongside the approval of Dupixent for COPD in the EU.
• Investor confidence in REGN was further boosted by the substantial increase in EYLEA HD sales and the progress of over 35 candidates in the company's product pipeline.

02.07.2024 - REGN Stock was up 0.2%

• Regeneron Pharmaceuticals outperformed expectations in the second quarter, reporting earnings per share of $11.56, marking a 13% increase from the previous year, and total revenues of $3.54 billion, a 12% rise.
• The strong demand for eczema and eye treatments like Dupixent and Eylea HD significantly contributed to the company's impressive performance, driving a positive movement in its stock value.
• The company's ability to meet market demand for its innovative pharmaceutical products, resulting in better-than-anticipated results and revenue growth, has bolstered investor confidence and elevated its stock price.
• Regeneron's success in delivering popular treatments and surpassing earnings projections has pushed its stock on an upward trajectory, outperforming its industry counterparts and fostering a favorable market outlook.